Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles

Nature Chemical Biology

Volumn 8, Issue 5, 2012, Pages 471-476

  Serafimova, Iana M ^a,b   Pufall, Miles A ^b,c   Krishnan, Shyam ^b   Duda, Katarzyna ^d   Cohen, Michael S ^a,b,e   Maglathlin, Rebecca L ^a,b   McFarland, Jesse M ^b   Miller, Rand M ^a,b   Frödin, Morten ^d   Taunton, Jack ^a,b,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACRYLAMIDE; ALKENE; CYSTEINE; ELECTROPHILE; MOLECULAR SCAFFOLD; NITRILE; PROTEIN P90; PROTEIN S6; THIOL;

ADDITION REACTION; ARTICLE; CELL ACTIVITY; CHEMICAL REACTION KINETICS; CONTROLLED STUDY; COVALENT BOND; CRYSTAL STRUCTURE; HUMAN; HUMAN CELL; HUMAN TISSUE; PH; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN MODIFICATION; PROTEIN PURIFICATION; PROTEIN UNFOLDING; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 84859845948     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.925     Document Type: Article

References (28)

1. Copeland, R.A., Pompliano, D.L. & Meek, T.D. Opinion - Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug Discov. 5, 730-739 (2006).
2. Potashman, M.H. & Duggan, M.E. Covalent modifiers: An orthogonal approach to drug design. J. Med. Chem. 52, 1231-1246 (2009).
3. Smith, A.J.T., Zhang, X.Y., Leach, A.G. & Houk, K.N. Beyond picomolar affinities: Quantitative aspects of noncovalent and covalent binding of drugs to proteins. J. Med. Chem. 52, 225-233 (2009).
4. Singh, J., Petter, R.C., Baillie, T.A. & Whitty, A. The resurgence of covalent drugs. Nat. Rev. Drug Discov. 10, 307-317 (2011).
5. Fry, D.W. et al. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc. Natl. Acad. Sci. USA 95, 12022-12027 (1998).
6. Cohen, M.S., Zhang, C., Shokat, K.M. & Taunton, J. Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science 308, 1318-1321 (2005).
7. Honigberg, L.A. et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl. Acad. Sci. USA 107, 13075-13080 (2010).
8. Zhou, W. et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462, 1070-1074 (2009).
9. Zhou, W. et al. A structure-guided approach to creating covalent FGFR inhibitors. Chem. Biol. 17, 285-295 (2010).
10. Hagel, M. et al. Selective irreversible inhibition of a protease by targeting a noncatalytic cysteine. Nat. Chem. Biol. 7, 22-24 (2011).
11. Leproult, E., Barluenga, S., Moras, D., Wurtz, J.M. & Winssinger, N. Cysteine mapping in conformationally distinct kinase nucleotide binding sites: Application to the design of selective covalent inhibitors. J. Med. Chem. 54, 1347-1355 (2011).
12. Zhang, J., Yang, P.L. & Gray, N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9, 28-39 (2009).
13. Wissner, A. et al. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J. Med. Chem. 46, 49-63 (2003).
14. Weerapana, E. et al. Quantitative reactivity profiling predicts functional cysteines in proteomes. Nature 468, 790-795 (2010).
15. Uetrecht, J. Idiosyncratic drug reactions: Past, present, and future. Chem. Res. Toxicol. 21, 84-92 (2008).
16. Evans, D.C., Watt, A.P., Nicoll-Griffith, D.A. & Baillie, T.A. Drug-protein adducts: An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 17, 3-16 (2004).
17. Park, B.K. et al. Managing the challenge of chemically reactive metabolites in drug development. Nat. Rev. Drug Discov. 10, 292-306 (2011).
18. Lee, G. et al. Novel inhibitors of hepatitis C virus RNA-dependent RNA polymerases. J. Mol. Biol. 357, 1051-1057 (2006).
19. Patch, R.J. et al. Identification of diaryl ether-based ligands for estrogen-related receptor a potential antidiabetic agents. J. Med. Chem. 54, 788-808 (2011).
20. Pritchard, R.B., Lough, C.E., Currie, D.J. & Holmes, H.L. Equilibrium reactions of N-butanethiol with some conjugated heteroenoid compounds. Can. J. Chem. 46, 775-781 (1968).
21. Pearson, R.G. & Dillon, R.L. Rates of ionization of pseudo acids. IV. Relation between rates and equilibria. J. Am. Chem. Soc. 75, 2439-2443 (1953).
22. Cohen, M.S., Hadjivassiliou, H. & Taunton, J. A clickable inhibitor reveals context-dependent autoactivation of p90 RSK. Nat. Chem. Biol. 3, 156-160 (2007).
23. Fabian, M.A. et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23, 329-336 (2005).
24. Frödin, M. & Gammeltoft, S. Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol. Cell. Endocrinol. 151, 65-77 (1999).
25. Doehn, U. et al. RSK Is a principal effector of the RAS-ERK pathway for eliciting a coordinate promotile/invasive gene program and phenotype in epithelial cells. Mol. Cell 35, 511-522 (2009).
26. Kang, S. et al. p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells. J. Clin. Invest. 120, 1165-1177 (2010).
27. Smolen, G.A. et al. A genome-wide RNAi screen identifies multiple RSK-dependent regulators of cell migration. Genes Dev. 24, 2654-2665 (2010).
28. Malakhova, M. et al. Structural basis for activation of the autoinhibitory C-terminal kinase domain of p90 RSK2. Nat. Struct. Mol. Biol. 15, 112-113 (2008).